RGD Reference Report - Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.

Authors: Gout, Stephanie  Brambilla, Elisabeth  Boudria, Asma  Drissi, Romain  Lantuejoul, Sylvie  Gazzeri, Sylvie  Eymin, Beatrice 
Citation: Gout S, etal., PLoS One. 2012;7(10):e46539. doi: 10.1371/journal.pone.0046539. Epub 2012 Oct 10.
RGD ID: 150429662
Pubmed: PMID:23071587   (View Abstract at PubMed)
PMCID: PMC3468597   (View Article at PubMed Central)
DOI: DOI:10.1371/journal.pone.0046539   (Journal Full-text)

Splicing abnormalities frequently occur in cancer. A key role as splice site choice regulator is played by the members of the SR (Ser/Arg-rich) family of proteins. We recently demonstrated that SRSF2 is involved in cisplatin-mediated apoptosis of human lung carcinoma cell lines. In this study, by using immunohistochemistry, we demonstrate that the SR proteins SRSF1 and SRSF2 are overexpressed in 63% and 65% of lung adenocarcinoma (ADC) as well as in 68% and 91% of squamous cell lung carcinoma (SCC), respectively, compared to normal lung epithelial cells. In addition, we show that SRSF2 overexpression correlates with high level of phosphorylated SRSF2 in both ADC (p<0.0001) and SCC (p = 0.02), indicating that SRSF2 mostly accumulates under a phosphorylated form in lung tumors. Consistently, we further show that the SR-phosphorylating kinases SRPK1 and SRPK2 are upregulated in 92% and 94% of ADC as well as in 72% and 68% of SCC, respectively. P-SRSF2 and SRPK2 scores are correlated in ADC (p = 0.01). Using lung adenocarcinoma cell lines, we demonstrate that SRSF1 overexpression leads to a more invasive phenotype, evidenced by activation of PI3K/AKT and p42/44MAPK signaling pathways, increased growth capacity in soft agar, acquisition of mesenchymal markers such as E cadherin loss, vimentin and fibronectin gain, and increased resistance to chemotherapies. Finally, we provide evidence that high levels of SRSF1 and P-SRSF2 proteins are associated with extensive stage (III-IV) in ADC. Taken together, these results indicate that a global deregulation of pre-mRNA splicing regulators occurs during lung tumorigenesis and does not predict same outcome in both Non Small Cell Lung Carcinoma histological sub-types, likely contributing to a more aggressive phenotype in adenocarcinoma.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
lung adenocarcinoma severityIEP 150429662; 150429662 RGD 
lung adenocarcinoma severityISOSRSF1 (Homo sapiens)150429662; 150429662 RGD 
lung adenocarcinoma severityISOSRSF2 (Homo sapiens)150429662; 150429662 RGD 
lung non-small cell carcinoma severityIEP 150429662 RGD 
lung non-small cell carcinoma  IEP 150429662protein:increased expression:lung epithelium and nucleusRGD 
lung non-small cell carcinoma severityISOSRSF1 (Homo sapiens)150429662; 150429662 RGD 
lung non-small cell carcinoma  ISOSRSF2 (Homo sapiens)150429662; 150429662protein:increased expression:lung epithelium and nucleusRGD 
lung squamous cell carcinoma  IEP 150429662protein:increased expression:lung epitheliumRGD 
lung squamous cell carcinoma  IEP 150429662protein:increased expression:lung epithelium and nucleusRGD 
lung squamous cell carcinoma  ISOSRSF1 (Homo sapiens)150429662; 150429662protein:increased expression:lung epitheliumRGD 
lung squamous cell carcinoma  ISOSRSF2 (Homo sapiens)150429662; 150429662protein:increased expression:lung epithelium and nucleusRGD 

Objects Annotated

Genes (Rattus norvegicus)
Srsf1  (serine and arginine rich splicing factor 1)
Srsf2  (serine and arginine rich splicing factor 2)

Genes (Mus musculus)
Srsf1  (serine and arginine-rich splicing factor 1)
Srsf2  (serine and arginine-rich splicing factor 2)

Genes (Homo sapiens)
SRSF1  (serine and arginine rich splicing factor 1)
SRSF2  (serine and arginine rich splicing factor 2)


Additional Information